Fact CheckerSign in

NCT05819944Recruiting

A Trial Evaluating Novel Technologies for the Diagnosis of Asthma The LUNG-TECH Trial

A Trial Evaluating Novel Technologies for the Diagnosis of Asthma

Source: ClinicalTrials.gov · Last updated 6 Jul 2026

Brief summary (registry, in English)

This trial aims to evaluate novel diagnostic technologies for asthma in 3 different pathways providing the necessary evidence-base to allow adoption into clinical practice: * Pathway 1 evaluates whether the technology can distinguish between people with asthma and healthy volunteers, and other respiratory conditions in a well characterised secondary-care population and whether the parameters they measure correlate with the current standard diagnostic tests; * Pathway 2 assesses whether the technology can accurately diagnose asthma (either independently or alongside current diagnostic tests) in a primary care population of patients where there is a clinical suspicion of asthma; * Pathway 3 explores the ability of the technology to identify clinically important phenotypic characteristics which are difficult to measure in primary care and/or significantly impact on patient management and treatment The novel technology and devices will be entered into the pathway most suited to their stage of development, with this study design also allowing information collected for participants with a confirmed diagnosis of asthma in pathways 1 or 2 to be included in pathway 3. Participants will undergo the investigations currently used to diagnose asthma as well as using the novel devices being investigated in the relevant pathway.

Status (registry)
Recruiting
Study type
Observational
Enrollment
356 (estimated)
First submitted
20 Feb 2023
Start date
9 Jan 2023
Primary completion date
1 Sept 2026
Lead sponsor
Portsmouth Hospitals NHS Trust
Diseases
Asthma
NCT number
NCT05819944

What you commit to

  • Study type: Observational
  • Planned participants: 356
  • From 9 Jan 2023 to the primary completion date, 1 Sept 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Never smoker or ex-smoker with ≤10 pack-years smoking history, and stopped smoking at least 6-months prior to enrolment

Other illness

  • • Known clinically significant chest wall, neuromuscular, cardiac or other co-morbidity or abnormality that would affect spirometry and/or other measures of lung function/inflammation (in the opinion of the investigator)
    • Respiratory tract infection/exacerbation of respiratory condition requiring systemic corticosteroids and/or antibiotic treatment within the last 2 weeks
    • Current smokers or Ex-smokers with \>20 PYH (other than COPD and asthma with significant smoking history group)
    • The participant is unable to provide informed consent or is unable to complete the study procedures
    • Healthy Volunteers:
  • No current clinical diagnosis of (or treatment for) a respiratory disease and no treatment for a respiratory tract Infection within the last 6 months

Other

  • Non-obstructive spirometry

Who the study is looking for

  • • Diagnosis confirmed by a specialist supported by any of the following within the last 5-years: i) Evidence of variable and/or reversible airflow obstruction
  • FEV1/FVC ratio \<70% on spirometry with FEV1 ≥12% and 200 ml increase post-BD or
  • FEV1 variability ≥20% between clinic visits within 12-months or
  • R5-R20 ≥0.1kPa/(L/s) with ≥40% improvement post-BD or ii) Evidence of significant peak expiratory flow (PEF) variability
  • ≥ 20% PEF variability iii) Evidence of airway hyperresponsiveness (AHR)
  • Positive methacholine challenge test (PD20 ≤8mg/ml) or equivalent iv) Evidence of T2 airway inflammation
  • FeNO ≥40ppb
    • Poor disease control evidenced by an ACQ-6 score ≥1.5
    • Not on a biologic therapy for severe asthma

Age in the registry: 17 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Portsmouth Hospitals University NHS Trust
Coordinator of this site? Confirm its status
PortsmouthUnited KingdomRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.